Stock ticker :
NASDAQ
AMGN
AS OF
Jan 19, closing price
Price
$231.30
Change
-$2.53 (-1.08%)
Capitalization
$130.3b
AMGN
Stock ticker :
NASDAQ
18 days until earnings call
Intraday data for
Jan 19, closing price
Price
$231.30
Change
-$2.53 (-1.08%)
Capitalization
$130.3b

(AMGN) Stock Forecast and AI Recommendations

a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor

Amgen (AMGN) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
A.I.dvisor published
a Summary for AMGN with price predictions.
4:00 PM EST Jan 19

AMGN sees MACD Histogram just turned negative

AMGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 19, 2022. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 27 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 66%.

Stock Forecast, Price, News, Quote

Current price $231.30 crossed the support line at $233.15 and is trading between $233.15 support and $215.41 resistance lines. Throughout the month of 12/16/21 - 01/19/22, the price experienced a +4% Uptrend, while the week of 01/11/22 - 01/19/22 shows a -0.46% Downtrend.

Technical Analysis (Indicators)
Bearish Trend Analysis

The 10-day RSI Indicator for AMGN moved out of overbought territory on January 18, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 22 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

AMGN broke above its upper Bollinger Band on January 14, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 173 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.

The Aroon Indicator entered an Uptrend today. In 130 of 271 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (15.848) is very high in comparison to the industry average of (4.977). P/E Ratio (23.866) is within average values for comparable stocks, (29.340). Projected Growth (PEG Ratio) (1.665) is also within normal values, averaging (2.436). Dividend Yield (0.030) settles around the average of (0.025) among similar stocks. P/S Ratio (5.189) is also within normal values, averaging (4.445).

A.I.dvisor published
Amgen Earnings Data

AMGN is expected to report earnings to fall 11.99% to $4.11 per share on February 07

Amgen AMGN Stock Earnings Report
Q4'21
Est.
$4.11
Q3'21
Beat
by $0.38
Q2'21
Beat
by $0.29
Q1'21
Missed
by $0.35
Q4'20
Beat
by $0.45
The last earnings report on November 02 showed earnings per share of $4.67, beating the estimate of $4.29. With 2.04M shares outstanding, the current market capitalization sits at 130.28B.
A.I.dvisor found
Amgen Dividends
AMGN paid dividends on December 08, 2021
Amgen AMGN Stock Dividends
А dividend of $1.76 per share was paid with a record date of December 08, 2021, and an ex-dividend date of November 15, 2021. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Biotechnology
Address One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
Phone +1 805 447-1000
Employees 19200
Web https://www.amgen.com
AMGN

Select Stock attributes to show

Capitalization 130B
P/E Ratio 23.87
Risk (Beta) 0.56
Dividend Yield 0.03
Total Cash 12.9B
Total Cash/Share 22.94
Total Debt 37.6B
Total Debt/Equity 140.82
Projected Growth (PEG Ratio) 1.67
Revenue/Share (as % of the share price) 45%
Revenue 25.8B
ROE N/A
Book Value 8.217B
P/B Ratio 15.85
Cash Flow N/A
Earnings 9.770
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 32B
Current Ratio 1.64
Current Revenue Per Employee 275,967.10
Dividends Per Share - Security 1.76
EBITDA 11B
Float N/A
Float - Current N/A
Gross Income Margin 76.01
Revenue To Assets 8.65
Shares Held By Institutions 926B
Shares Outstanding - Current N/A
Total Liabilities 56.8B
Total Volume MTD N/A
Value Over
Gain YTD 2.814
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 130.28b USD
P/E Ratio 23.866348
Total Cash 12.92b USD
Projected Growth 1.67
Total Debt 37.58b USD
Revenue 25.77b USD
Risk (Beta) 0.56
Dividend Yield 0.03
Total Cash/Share 22.94
Total Debt/Equity 140.82
Revenue/Share 45.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD